Kura Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Okay. Well. Welcome, everybody. I'm Marty Auster. I'm the lead SMID Cap Biotech Analyst at Crédit Suisse. Thanks for joining us again at the 29th Annual Credit Suisse Healthcare Conference.
Up next, we've got Kura oncology. I've got Troy Wilson, President and CEO of the company, to make a presentation on Kura Oncology. We'll be conducting maybe a brief Q&A at the end, time allowing. If anybody in the audience has any questions, please shoot me an e-mail, and I'll work those into the -- to that brief Q&A session at the end of the presentation.
Troy, let me hand it over to you. Thanks for joining us today.
Thank you, Marty, and thanks to you and Crédit Suisse for the invitation to participate in your conference. Good morning, everyone. Today, I'll be giving an overview of Kura Oncology and the progress that we're making in advancing our 2 wholly owned assets
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |